An Australian vote for pharma: biosimilars
This article was originally published in Scrip
Somatropin is the only biosimilar product on the Australian market. (In Europe, by contrast, 17 biosimilars of five different molecules have been approved since 2006.) This synthetic growth hormone recorded sales of $45,000 in 2009, although the market is still very much dominated by the original branded product: Pfizer's Genotropin and Genotropin MiniQuick. Three years after the first biosimilar was launched, the biosimilar somatropin market accounted for 0.4% of total somatropin sales.
You may also be interested in...
Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.